Deals this week: CONMED Corporation, Dentsply Sirona, HighLife

25 January 2019 (Last Updated January 24th, 2019 12:29)

CONMED Corporation plans to raise $275m by issuing convertible senior notes due 2024 in a private offering to qualified institutional buyers.

CONMED Corporation plans to raise $275m by issuing convertible senior notes due 2024 in a private offering to qualified institutional buyers.

The initial purchasers will have an option to purchase an additional $41.25m in aggregate principal amount of the notes.

A portion of net proceeds will be used for paying the cost of certain convertible note hedge transactions. The remaining amount along with borrowings and cash will be used to finance the acquisition of Buffalo Filter and Palmerton Holdings.

Based in the US, CONMED Corporation is a medical technology company providing surgical devices and equipment for minimally invasive procedures.

Dentsply Sirona has formed a strategic collaboration with Carbon to deliver innovative denture materials for the latter’s digital 3D printing production solutions.

The two companies propose to develop a complete digital denture solution, which is superior in terms of strength and aesthetics through the collaboration.

The collaboration will enable Dentsply Sirona to expand laboratory efficiency and improve state-of-the-art materials in the 3D dental printing market.

Dentsply Sirona is a manufacturer of professional dental products and technologies, while Carbon is a digital manufacturing company. Both companies are based in the US.

“The collaboration will enable Dentsply Sirona to expand laboratory efficiency and improve state-of-the-art materials in the 3D dental printing market.”

HighLife has raised €32m ($36.4m) in an equity financing (Series B) round co-led by US Venture Partners and Andera Partners.

Sectoral Asset Management and Sofinnova Partners also participated in the funding round.

Funds raised will be used towards the development of HighLife’s transcatheter transseptal mitral valve implantation programme.

The company has engaged Bryan Garnier & Co (Paris) as its private placement agent for the transaction.

Based in France, HighLife is engaged in the development of unique transcatheter mitral valve replacement (TMVR) system for treating patients with mitral regurgitation.

Modulated Imaging has raised $7m in a series B funding round led by Pangaea Ventures.

Other investors who participated in the financing round include Fresenius Medical Care Ventures, Grey Sky Venture Partners, and Mitsubishi UFJ Capital.

Proceeds from the funding round will be used to fund the commercialisation of Clarifi Imaging System, which has been cleared by the US FDA.

Based in the US, Modulated Imaging is engaged in developing optical imaging solutions for non-invasive assessment of tissue health.